Finch Therapeutics Group (FNCH) Competitors $12.00 +0.75 (+6.67%) (As of 11/14/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends FNCH vs. ALGS, SYRS, CRVO, QNCX, BYSI, SPRO, ALXO, VNRX, MNPR, and VORShould you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Aligos Therapeutics (ALGS), Syros Pharmaceuticals (SYRS), CervoMed (CRVO), Quince Therapeutics (QNCX), BeyondSpring (BYSI), Spero Therapeutics (SPRO), ALX Oncology (ALXO), VolitionRx (VNRX), Monopar Therapeutics (MNPR), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry. Finch Therapeutics Group vs. Aligos Therapeutics Syros Pharmaceuticals CervoMed Quince Therapeutics BeyondSpring Spero Therapeutics ALX Oncology VolitionRx Monopar Therapeutics Vor Biopharma Aligos Therapeutics (NASDAQ:ALGS) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, community ranking, profitability, earnings, institutional ownership and risk. Which has more risk and volatility, ALGS or FNCH? Aligos Therapeutics has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Does the media prefer ALGS or FNCH? In the previous week, Aligos Therapeutics had 9 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 9 mentions for Aligos Therapeutics and 0 mentions for Finch Therapeutics Group. Aligos Therapeutics' average media sentiment score of 0.24 beat Finch Therapeutics Group's score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aligos Therapeutics Neutral Finch Therapeutics Group Neutral Which has preferable valuation & earnings, ALGS or FNCH? Finch Therapeutics Group has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAligos Therapeutics$15.53M4.01-$87.68M-$13.32-1.46Finch Therapeutics Group$110K175.64-$74.75M-$8.82-1.36 Do analysts rate ALGS or FNCH? Aligos Therapeutics currently has a consensus target price of $75.00, indicating a potential upside of 285.41%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Aligos Therapeutics is more favorable than Finch Therapeutics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ALGS or FNCH more profitable? Finch Therapeutics Group has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,283.19%. Finch Therapeutics Group's return on equity of -69.14% beat Aligos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aligos Therapeutics-1,283.19% -114.34% -64.58% Finch Therapeutics Group N/A -69.14%-26.92% Does the MarketBeat Community prefer ALGS or FNCH? Aligos Therapeutics received 17 more outperform votes than Finch Therapeutics Group when rated by MarketBeat users. Likewise, 65.85% of users gave Aligos Therapeutics an outperform vote while only 52.63% of users gave Finch Therapeutics Group an outperform vote. CompanyUnderperformOutperformAligos TherapeuticsOutperform Votes2765.85% Underperform Votes1434.15% Finch Therapeutics GroupOutperform Votes1052.63% Underperform Votes947.37% Do insiders & institutionals believe in ALGS or FNCH? 60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 8.8% of Aligos Therapeutics shares are held by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryAligos Therapeutics beats Finch Therapeutics Group on 10 of the 18 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Finch Therapeutics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FNCH vs. The Competition Export to ExcelMetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.32M$3.06B$5.34B$8.88BDividend YieldN/A1.76%4.98%4.04%P/E Ratio-1.3646.30132.1317.45Price / Sales175.64426.611,259.0698.78Price / CashN/A179.8139.1436.42Price / Book0.844.296.265.86Net Income-$74.75M-$42.42M$118.47M$224.86M7 Day Performance4.35%-5.83%-2.23%-0.93%1 Month Performance3.00%1.85%2.38%3.66%1 Year Performance218.30%34.19%35.45%26.41% Finch Therapeutics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FNCHFinch Therapeutics GroupN/A$12.00+6.7%N/A+196.1%$19.32M$110,000.00-1.36190Gap UpALGSAligos Therapeutics4.171 of 5 stars$17.85+27.6%N/A+30.5%$57.12M$15.53M-1.3490Short Interest ↑Analyst RevisionTrading HaltedHigh Trading VolumeSYRSSyros Pharmaceuticals4.2301 of 5 stars$2.73-15.5%N/A-86.7%$73.25M$9.94M-0.90120Analyst ForecastShort Interest ↑News CoverageGap DownHigh Trading VolumeCRVOCervoMed1.219 of 5 stars$11.83-2.6%N/A+15.3%$72.99M$7.14M0.004Earnings ReportAnalyst ForecastShort Interest ↑News CoverageGap UpHigh Trading VolumeQNCXQuince Therapeutics2.6439 of 5 stars$1.68+1.2%N/A+75.3%$72.71MN/A-1.3360Short Interest ↑News CoverageBYSIBeyondSpringN/A$1.86-6.1%N/A+103.3%$72.60M$1.75M0.0080Gap DownSPROSpero Therapeutics4.7568 of 5 stars$1.32-0.8%N/A+18.0%$71.27M$103.78M4.0046Short Interest ↑News CoverageALXOALX Oncology3.4422 of 5 stars$1.34-9.5%N/A-84.1%$70.58MN/A-0.4540Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageVNRXVolitionRx2.0112 of 5 stars$0.75+5.6%N/A-8.4%$68.89M$976,516.00-1.8780Analyst ForecastNews CoverageGap DownMNPRMonopar Therapeutics3.6131 of 5 stars$17.25+3.5%N/A+1,132.3%$68.31MN/A-8.7610Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionVORVor Biopharma2.3876 of 5 stars$0.99-2.0%N/A-46.4%$67.69MN/A-0.60140Earnings Report Related Companies and Tools Related Companies ALGS Alternatives SYRS Alternatives CRVO Alternatives QNCX Alternatives BYSI Alternatives SPRO Alternatives ALXO Alternatives VNRX Alternatives MNPR Alternatives VOR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FNCH) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FNCH Stock Alerts